A medical assessment with a laptop, notes and a consultation

Indication · BMI · contraindications

Who can receive Wegovy? Indications and contraindications

In Sweden, Wegovy is approved for long-term weight management in adults and selected adolescents. This guide explains BMI criteria, associated conditions, contraindications and what doctors consider during assessment.

Book a doctor's appointment →Read about treatment

The preliminary check and the booking request are free. You pay the first month before the doctor's appointment.

Medical assessment by Dr Masoud Sorkhabi, senior consultant physician. Your first appointment takes place by video or in person in Gothenburg.

Prescription documents and a dosing plan for medical treatment

A generic injection pen, water and a notebook for a discussion of Wegovy treatment and costs

Two treatment approaches compared during a calm healthcare consultation

Quick answersbased on Swedish guidance

At what BMI?: BMI ≥30, or BMI ≥27 with a weight-related health condition such as type 2 diabetes, high blood pressure or sleep apnoea.
Who should not use it?: Allergy to semaglutide or its other ingredients is a contraindication. Treatment should not be used during pregnancy. Breastfeeding and other risk factors must be discussed with a doctor.
Is a doctor needed?: Yes. The final assessment is always individual and is made by a licensed doctor.

Treatment at viktbehandling.se

Weight-loss programme and cost

SEK 450 per month – first doctor's appointment by video included

Minimum 4 months (SEK 1,800 in total), then cancel whenever you like.

The first doctor's appointment with Dr Masoud Sorkhabi, senior consultant physician, takes place by video or in person in Gothenburg (in person +SEK 1,000 once). The monthly fee also covers the medical assessment, an individual treatment plan and follow-up as the doctor judges appropriate. If you have answered truthfully and the doctor says no for medical reasons, you pay only the first month.

Medication is not included in the programme price and is paid for separately at a pharmacy. If the doctor considers blood tests, a referral or other investigations necessary, these are at your own expense and are not included in the programme fee.

See what's included and what it costs How treatment works →

Medical disclaimer

All medical weight-loss treatment must be assessed by a licensed doctor based on individual factors. We do not recommend rapid weight loss. Information on this page does not replace healthcare.

In an emergency, call 112. For healthcare advice, contact 1177.

If you have thoughts of suicide, seek urgent help. Our safety information (Swedish) lists support options.

Buy prescription weight-loss medication only from licensed pharmacies with a valid prescription. Products sold outside the legal medicine supply chain may carry risks. Read the Swedish Medical Products Agency's guidance on buying medicines safely and report suspected adverse effects.

Patients always pay for medication separately at a Swedish pharmacy. Medication is never included in the programme price. We do not add a margin to the medication price.

If you have or suspect an eating disorder, contact your healthcare centre or visit Frisk & Fri. Weight-loss medication is not recommended in the presence of an eating disorder.

Medical content is fact-checked according to our policy.Editorial policy (Swedish)How we review our content Safety and urgent help (Swedish)

Approved indication in Sweden

Wegovy (semaglutide) is approved by EMA and the Swedish Medical Products Agency for:

Long-term weight management in adults, alongside a reduced-calorie diet and increased physical activity.
Long-term weight management in adolescents aged 12–17 with obesity and a body weight above 60 kg, following specialist assessment.

Unlike Mounjaro, Wegovy is not approved for type 2 diabetes. For diabetes, the semaglutide product used is Ozempic, which contains the same active substance but is a separate product with its own doses and reimbursement rules. Read more in Ozempic vs Wegovy.

BMI criteria for the weight-management indication

The official criteria for weight management are:

BMI ≥30 kg/m² (obesity), without a requirement for an associated condition.
BMI ≥27 kg/m² (overweight), combined with at least one weight-related health condition.

Weight-related conditions that may support treatment at BMI 27–30

Type 2 diabetes or prediabetes
Hypertension (high blood pressure)
Dyslipidaemia (abnormal blood lipids)
Obstructive sleep apnoea
Cardiovascular disease
Metabolic syndrome
Metabolic dysfunction-associated steatotic liver disease (MASLD)

What doctors consider beyond BMI

Doctors always make an overall assessment that also considers:

Medical history: previous illnesses, operations and medication
Previous weight-loss attempts: nutrition, exercise, other medicines and surgery
Mental health: eating disorders, depression and anxiety
Motivation and expectations: realistic goals and readiness for long-term treatment
Ability to combine treatment with nutrition and physical activity

Contraindications and important warnings

The EU product information lists allergy to semaglutide or its other ingredients as a contraindication. The doctor also needs to discuss pregnancy, breastfeeding and other risk factors.

Allergy to the active substance or other ingredients.
Pregnancy: treatment should not be used during pregnancy.
Breastfeeding: always discuss this with a doctor before treatment.
MTC or MEN 2: these are risk flags in our preliminary check, but are not listed as contraindications in the EU product information.

The preliminary check does not replace the doctor's individual assessment.

Precautions and individual assessment

Treatment requires particular assessment in people with:

Previous pancreatitis or ongoing gastrointestinal disease
Gallbladder disease or gallstones
Severely impaired kidney or liver function
Active or untreated diabetic retinopathy (with type 2 diabetes)
A history of an eating disorder
Use of insulin or sulphonylureas (risk of hypoglycaemia)

Age limits

Wegovy is approved for adults aged 18 and over and, following an extended indication in 2023, for adolescents aged 12–17 with obesity and a body weight above 60 kg. Use in adolescents requires specialist assessment and a separate follow-up structure. In older adults (≥65), treatment may be appropriate but requires individual assessment of kidney function and associated conditions.

Pregnancy and fertility

Semaglutide is not recommended during pregnancy or breastfeeding. Women who could become pregnant should use effective contraception during treatment. Discuss contraception, other medicines and any plans for pregnancy with a doctor.

What does Vikt's assessment involve?

When you send a preliminary request:

You provide your contact details and preferred option. The booking form does not collect health information.
We review your request and normally respond within one business day.
We confirm a time for your first doctor's appointment, by video or in person in Gothenburg, and send you a link to pay the first month. The doctor carries out the medical assessment at the appointment.
A licensed doctor always makes the final assessment and issues any prescription.

Try our preliminary assessment (Swedish) — it provides guidance, not a diagnosis, and does not replace a medical assessment. If you wish to proceed, you can send a free booking request.

What if the indication is not met?

If your BMI or health profile does not meet the approved criteria, medical GLP-1 treatment is normally not appropriate. Other options that may be discussed include:

Lifestyle-based weight management and nutrition guidance
Structured exercise and behavioural support
Follow-up of underlying conditions where appropriate (e.g. insulin resistance or PCOS)
Reassessment if your health changes

Questions about who can receive Wegovy

At what BMI can I receive Wegovy?+

Under the EMA-approved indication, treatment may be considered at BMI ≥30 (obesity), or BMI ≥27 with a weight-related health condition such as type 2 diabetes, high blood pressure, sleep apnoea, dyslipidaemia or cardiovascular disease.

Is meeting the BMI criteria enough?+

No. BMI is a starting point. A licensed doctor always makes the final individual assessment, considering your overall health, previous attempts, contraindications and expected benefits.

Who should not use Wegovy?+

The EU product information lists allergy to semaglutide or its other ingredients as a contraindication. Pregnancy and other risk factors also require medical assessment. MTC and MEN 2 are risk flags in our preliminary check, but are not listed as contraindications in the EU product information.

Can adolescents receive Wegovy?+

In the EU, Wegovy is also approved for adolescents aged 12–17 with obesity and a body weight above 60 kg, but use in this age group requires specialist assessment. The main indication is for adults aged 18 and over.

Do previous weight-loss attempts matter?+

Yes. Doctors often ask about previous attempts involving nutrition, exercise or other medicines. Medical treatment may be more relevant when lifestyle changes have not had a sufficient effect.

What happens during the assessment?+

The first step is a free request with your contact details and preferred option. The booking form does not collect health information. We review the request and confirm a time for your first doctor's appointment, by video or in person in Gothenburg, where the doctor carries out an individual medical assessment.

Next step